Member Info for OAPK20

“ Simply load your sample, antibodies, and reagents, and insert the sample plate and cartridge into your Simple Western instrument. Come back to fully analyzed results in as little as 3 hours.”

Would you be recruiting for Manufacturing lab assistants, Research Associates Reagent manufacturing, Manufacturing Technicians Cartridge assembly, Account Executives ?

If they don’t want them……..

Approaching key date anniversary of submission. Average US pendency is around 25 months. Be interesting to see if there is an update regarding the patent application around or after the application anniversary.

Will CIZ wait until the grant of the patent for their CIZ1b lung cancer test process application to an existing testing platform.

Guess who's back, back again

Shady's back, tell a friend

Guess who's back, guess who's back,

Guess who's back. Guess who's back?

Currently up 56% $4.41, after market Bronby. Fingers crossed it holds then see where tomorrow’s pre-market takes CDT.

Only $6.32 to go then Bronby 😁

Interesting to note- BioTechne CEO.

Last week, I visited Europe to connect with customers, investors, and, of course, our Bio-Techne teams. Our team in Bristol, U.K. is always very engaging and I enjoyed seeing the progress across the Small Molecule business unit, specifically around our GMP project. In Abingdon, U.K., our EMEA headquarters, I enjoyed a deep dive into our European business and an interactive town hall.

Britain will ink a new trade deal with Texas this week,

Worth a monster £2.3trillion, it is bigger than the economies of Canada, Russia and Australia.

The deal will make it easier for UK and Texan companies in sectors such as energy, life sciences and professional services to do business together.

US President Joe Biden does not want to do a US-wide trade deal with the UK, so ministers have been signing individual deals with American states.

Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit") today announced the opening of cutting-edge laboratory space in Cambridge, United Kingdom, a global centre for research and development for companies at the forefront of life science innovation. This strategic acquisition marks a pivotal milestone for Conduit, positioning the Company for portfolio expansion, enhanced development capabilities, and growth of a robust intellectual property portfolio.

The laboratory space in Cambridge sits within 150 acres and two million square feet of high technology and laboratory buildings, housing nearly 7,000 people at over 130 companies that range from exciting start-ups to some of the world's leading technology and life science businesses.

At Conduit’s new laboratory, the scientific team will focus on strengthening and extending the Company’s intellectual property portfolio using solid form technology to maximise out-licensing value. The new centre of excellence will function as the nucleus of the Company's workstream management platform, a system integrating the expertise of Conduit’s management and scientific teams with complimentary algorithmic and artificial intelligence tools. The Company believes this will streamline operations including asset selection and monitoring key deliverables within its clinical trials.

“Our new laboratory serves as a dynamic base for Conduit's breakthrough endeavours, providing an optimal environment to progress and expand upon our existing asset portfolio while also facilitating a generation of new intellectual property,” said Dr. David Tapolczay, Chief Executive Officer of Conduit. “This initiative reaffirms our commitment to leading the charge in pharmaceutical innovation, collaborating closely with the celebrated scientific community in Cambridge, a prominent global life sciences hub that consistently pushes the boundaries of what is possible and develops life-changing advancements for patients.”

We are delighted to congratulate Bill Behnke on his appointment to the Conquer Cancer Board of Directors. Bill leads Cizzle Biotechnology’s business development in the USA and was responsible for identifying and facilitating the Company’s deal with CorePath Laboratories, a full-service cancer reference laboratory, to develop and offer Cizzle Biotechnology plc’s proprietary early-stage lung cancer test in the USA.

Conquer Cancer, the ASCO Foundation, funds research for every cancer, to help every patient, everywhere. Since 1984, its Grants & Awards program has awarded more than $182 million in funding through over 8,700 grants and awards to medical students, residents, fellows, scientists, and oncologists in 88 countries.

Bill has decades of success in delivering major revenues and raising capital from VC, PE and private investors. He continues to promote support for major cancer charities and advocacy groups such as the Leukemia and Lymphoma Society, Conquer Cancer, the ASCO Foundation, the AYA Cancer Foundation and the South Texas Blood and Tissue Center.

His appointment to the Conquer Cancer Board will enable Bill to further expand his current programme with Cizzle Biotechnology plc, providing access to healthcare corporations, hospitals, clinicians and key opinion leaders involved in driving early-stage cancer detection.

Learn more about this great organisation at: www.conquer.org https://brnw.ch/21wHIdG

Premier Fund Managers Ltd - 6.8%

Don’t upset Neilin with you’re 1.8 chart wish 😁

Maybe more than one group of PI’s with decent holdings. Might be one with a collective holding above 4%.

Scooby doooby dooo

Is there an open pit mining operation available with smelter producing Copper and Gold ?

RE: Make of this what you will23 Nov 2023 18:18

"The Ciz1 b-variant peptide and/or fibrinogen/Ciz1 b-variant peptide complex may be released from the exosomal component by detergent treatment, such as SDS treatment."

Tumor-derived exosomal components: the multifaceted roles and mechanisms in breast cancer metastasis

https://www.nature.com/articles/s41419-021-03825-2

"The blocking or inhibition of exosome-derived components might represent a growing body of exciting strategies for combating metastasis."

This paragraph is interesting. Might interest Neil ?

In the lung metastatic mouse model, the BC exosomal miR-183-5p could transfer to macrophages to promote the secretion of pro-inflammatory cytokines interleukin-1b (IL-1β), IL-6, and tumor necrosis factor-α, via repressing phosphatase 2 catalytic subunit alpha (PPP2CA)60. Obviously, the knockdown of miR-183-5p in 4T1 exosomes inhibited BC growth and metastasis in the BC lung metastasis model. In another search, mimic miR-33 delivered by 4T1 cell exosome was able to induce M1 polarization in macrophages, resulted in improved antitumor effect61. It was known that tissue inhibitors of metalloproteinase 2 (TIMP2) belonged to the TIMP family and could effectively inhibit the invasion and metastasis of tumors. Wang et al. confirmed that in the BC metastatic mouse model, the overexpression of tumor-derived miR-4443 was of high capacity to induce BC liver metastasis38. The conveying exosomal miR-4443 could break the natural barriers, which was accompanied by impaired TIMP2 and consequently upregulated MMP-2 in both the primary tumor and metastasis liver sites, resulted in engrafting in the new microenvironment.

Jace/Green I had previously raised similar. Think Neilin had for info but can’t remember fully.

This is from 2012 - “restrains proliferation of lung cancer cells”

Conflict of interest statement: The findings reported in this paper arise directly out of basic research at the University of York (York, Yorkshire, United Kingdom) on the Ciz1 protein and its role in the spatial and temporal organization of DNA replication. The findings are the result of an academic and commercial collaboration, funded in part by Cizzle Biotech, which is a spin-out company of the University of York. G.H. and D.C. are partially funded by Cizzle Biotech. D.C. and J.F.X.A hold shares in Cizzle Biotech.

Fig. 4. Suppression of the expression of the Ciz1 b-variant restrains proliferation of lung cancer cells. (A) Effect of luciferase control shRNA (luc) and b-variant junction-selective RNAi sequence 4 on SBC5 cells, expressed as fold increase in cell number over 4 d after induction of shRNA with doxycycline at days 1 and 3 (gray arrowheads). RNAi sequences are described in Fig. S6. (B) RT-PCR analysis of Ciz1 AD (primers P1/P2), b-variant (P4/P3), and actin (P11/P12) in SBC5 b-variant shRNA 4 cells, without (− dox) and with induction of expression at 26 h (+) or as two doses (++) administered at 26 h and 1 h before isolation. (C) Detergent-resistant endogenous b-variant protein (antibody 2B, green) in the nucleus of SBC5 b-variant shRNA 4 cells 2 d after induction of shRNA. DNA is blue. (Scale bar, 10 microns.) (D) Xenograft tumor formation in mice. Control mice were inoculated with SBC5 b-variant shRNA 4 cells and maintained in the absence of doxycycline (open circles, group 1). Additional cohorts (filled circles) were given doxycycline continuously from 3 d before inoculation (group 3, Right) or after 21 d (group 2, Left). For the comparison of groups 1 and 2, mice with tumors less than 100 mg at 21 d were discounted, creating cohorts with low variation. Graphs show mean tumor weight from 10–15 animals, with SEM. (Data are given in Dataset S3.)

Https://www.shukaminerals.com/shareholderinformation

Warrants at 25p up for expiry 25/5/24.

Give their heads a wobble. 😜

Will it get to 20-25p and Warrant price pre news?

60,219,861 Ordinary Shares in issue

48.75% held by TR1 holders.

Free float of around 29,357,182

If that sounds about right this will move fast (up or down)

Helium or Zinc or something else ?

DTR 5:8:12 - (1) An issuer not falling within (2) must, in relation to shares admitted to trading on a regulated market, on receipt of a notification as soon as possible and in any event by not later than the end of the trading day following receipt of the notification make public all of the information contained in the notification.

DTR 5:8:3 - The notification to the issuer shall be effected as soon as possible, but not later than four trading days in the case of a non-UKissuer and two trading days in all other cases, after the date on which the relevant person:

(1) learns of the acquisition or disposal or of the possibility of exercising voting rights, or on which, having regard to the circumstances, should have learned of it, regardless of the date on which the acquisition, disposal or possibility of exercising voting rights takes effect; or

(2) is informed about the event mentioned in DTR 5.1.2 R (2).

And for the purposes of (1) above a person shall, in relation to a transaction to which he is a party or which he has instructed, be deemed to have knowledge of the acquisition, disposal or possibility to exercise voting rights no later than two trading days following the transaction in question and where a transaction is conditional upon the approval by public authorities of the transaction or on a future uncertain event the occurrence of which is outside the control of the parties to the agreement, the parties are deemed to have knowledge of the acquisition, disposal or possibility of exercising voting rights only when the relevant approvals are obtained or when the event happens.